How Academic Researchers and Policy Experts Use DrugPatentWatch

Books and Research Papers Citing DrugPatentWatch

All Years | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007

2025 — 11 Books and Research Papers Citing DrugPatentWatch

Gregory, A. (2025). Cellect Your Battles Wisely: Should Obviousness-Type Double Patenting Be Eliminated or Rehabilitated? U. Mass. L. Rev.
Gregory’s article examines the implications of obviousness-type double patenting in pharmaceutical patent law. DrugPatentWatch is cited to provide data on patent expirations and generic entry dates, offering empirical context to the discussion of patent term extensions and exclusivity periods. This citation underscores the importance of patent lifecycle analysis in understanding the effects of patenting strategies on market competition.

De Boni, L. A. B. (2025). Research Landscape of Repurposed Medications in Cancer Treatment: A Multi-Database Bibliometric Analysis of Eleven Off-Patent Therapeutics. Sjöström Journal of Pharmaceutical Sciences.
De Boni’s study conducts a bibliometric analysis of off-patent medications repurposed for cancer treatment. DrugPatentWatch is referenced to identify the patent status and market exclusivity of these drugs, providing a foundation for evaluating the commercial viability and competitive landscape of repurposed therapies. The citation highlights the role of patent data in assessing the strategic positioning of repurposed drugs in oncology.

Singh, S. K. (2025). Maximizing HCP Outreach with Segmentation: An AI/ML-based Approach. Journal of Computer Science and Technology.
Singh’s paper explores the use of AI and machine learning in segmenting healthcare professionals (HCPs) for targeted outreach. DrugPatentWatch is cited to provide insights into the patent status and exclusivity periods of pharmaceutical products, informing the segmentation strategy by identifying drugs nearing patent expiration. This application demonstrates how patent data can enhance marketing strategies by aligning them with the evolving market dynamics due to patent expirations.

Shi, Z., Wang, S., & Wang, Y. (2025). Midodrine plus propranolol: potential problems and controversies behind remarkable efficacy. Hepatology International, Springer, 2025
This paper examines the clinical efficacy of the combination therapy of midodrine and propranolol, focusing on the controversies surrounding its therapeutic use. DrugPatentWatch was cited primarily as a resource to track the patent status and exclusivity timelines of both drugs, which is crucial for assessing potential market competition and generic entry. The authors leveraged DrugPatentWatch data to analyze patent expiration dates, patent litigation history, and to explore how ongoing patents could influence the development of combination formulations or new indications. This insight aids pharmaceutical companies and researchers in strategic planning for drug lifecycle management and patent strategy.

Hassan, A. F., El-kott, A. F., AlShehri, M. A., et al. (2025). Construction of Zinc Oxide/Nickel Ferric-Layered Double Hydroxide Composite for Efficient Adsorption of Erythromycin: Kinetic and Thermodynamic Investigation. Water, Air, & Soil Pollution, Springer
This study explores the synthesis of a novel composite material for the adsorption and removal of erythromycin, a widely used antibiotic, from environmental samples. DrugPatentWatch was cited to provide critical patent landscape insights on erythromycin, highlighting active and expired patents related to the drug’s formulation and delivery. These patent insights helped the authors contextualize the significance of erythromycin’s patent status in motivating the development of environmental remediation technologies. The integration of patent data from DrugPatentWatch allowed the authors to link drug usage trends with environmental contamination challenges, emphasizing the relevance of patent monitoring in pharmaceutical and environmental research.

Monge, A., & Thai, L. (2025). Competition in the US Therapeutic Biologics Market. Office of the Assistant Secretary for Planning and Evaluation, U.S. Department of Health and Human Services.
Monge and Thai analyze the competitive landscape of the U.S. therapeutic biologics market. DrugPatentWatch is utilized to track patent expirations and the entry of biosimilars, offering empirical data to assess the impact of patent cliffs on market competition. The citation emphasizes the significance of patent expiration timelines in understanding the dynamics of biologics competition and market access.

Honey, H. (2025). Freedom to Operate (FTO) Analysis-Strategic IP Compliance for Indian Businesses. SSRN Electronic Journal.
Honey’s paper discusses strategies for conducting Freedom to Operate (FTO) analyses, focusing on intellectual property compliance for Indian pharmaceutical companies. DrugPatentWatch is cited to provide data on patent expirations and exclusivity periods, aiding in the identification of potential patent risks and opportunities for generic entry. This citation underscores the utility of patent data in formulating FTO strategies and navigating the global pharmaceutical patent landscape.

Reddy, K.J. Accessibility and Affordability of Technologies Innovations in Neurocognitive Rehabilitation, Springer, 2025.
This paper references DrugPatentWatch as a key resource for tracking the patent status of emerging neurocognitive rehabilitation technologies. It highlights how the database enables researchers and developers to identify which technologies are approaching patent expiration, thereby informing strategic decisions for affordable technology adoption and licensing. The author notes DrugPatentWatch’s utility in providing comprehensive patent landscapes that support cost-effective access to novel rehabilitation tools.

Anusha, A., Ponnekanti, K., Rajkamal, B., et al. Revolutionizing Oral Delivery: Enteric Capsules with Mini-Tablet Technology World Journal of Pharmaceutical Research, 2025.
In this study, DrugPatentWatch is cited as an essential tool for analyzing the patent environment around enteric capsule technologies. The authors used the platform to examine existing patents and identify white spaces for innovation in mini-tablet delivery systems. The paper emphasizes how DrugPatentWatch helped the research team avoid patent infringement while designing novel formulations, ultimately accelerating product development timelines.

Santoso, S.B., Pribadi, P., Hapsari, W.S., et al. Exploring the Role of DrugBank in Investigating Pharmacogenomic-Driven Novel Drug Development Jurnal Farmasi Sains, 2025
While primarily focused on DrugBank, this paper references DrugPatentWatch to complement drug patent data with pharmacogenomic insights. The authors leveraged DrugPatentWatch to validate patent statuses and exclusivity periods of candidate drugs identified through genomic analysis. This integrated approach underscored the importance of patent databases in bridging molecular research with market viability assessments.

Ejection Fraction: Heart Failure with Reduced Ejection Fraction, an Overview 2025, books.google.com
This book cites DrugPatentWatch to illustrate how patent monitoring informs pharmaceutical companies developing treatments for heart failure with reduced ejection fraction (HFrEF). It highlights DrugPatentWatch’s role in tracking patent expiration dates and patent disputes that affect drug availability and generic entry timing. The reference supports discussions on balancing innovation incentives with the need for affordable medication access in cardiovascular therapies.